hbsag

HBF-0259 is an inhibitors of hepatitis B virus surface antigen (HBsAg) secretion with an EC50 of 11.3 μM and a CC50 value of >50 μM in HepG2.2.15 cells. HBF-0259 had a EC50 of approximately 1.5 microM in a secondary, HBV-expressing cell line, with a concentration that exhibited 50% cytotoxicity of >50 microM. The equilibrium concentration of HBF-0259 in aqueous solution at physiological pH was 15 to 16 microM; the selective index was thus >9.

RG7834 (RO 7020322) is a highly selective and orally bioavailable inhibitor of HBV, targeting HBsAg, HBeAg, and HBV DNA with IC50s of 2.8 nM, 2.6 nM, and 3.2 nM, respectively, in dHepaRG Cells.

Oleana-2,12-dien-28-oic acid is an HBsAg and HBeAg inhibitor that significantly inhibits HBV deoxyribonucleic acid (HBV-DNA) replication in HepG2.2.15 cells, making it relevant for the study of hepatitis B virus infection.

Chamaechromone is a natural product isolated from the roots of Stellera chamaejasme L.. Chamaechromone has anti-HBV and insecticidal activity.

Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a bioactive peptide. It is one of the Aβ1–14 targeting peptides (B cell epitope) for UB-311.

ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

ZINC20451377 is a small molecule compound that binds with high affinity to the hepatitis B surface antigen (HBsAg), with a dissociation constant (Kd) of 65.3 nM. It reduces HBsAg levels and HBV particle secretion in HBV cell culture models.

AB-161 is an orally active destabilizer of HBV RNA and an inhibitor of PAPD5/7, primarily targeting the liver. It treats hepatitis B virus (HBV) infection by reducing hepatitis B surface antigen (HBsAg) levels, exhibiting an EC50 value of 2.2 nM for HBsAg. AB-161 is applicable in HBV infection research.

BA-AZT1 acts as an inhibitor of HBV polymerase (HBV polymerase) and sodium taurocholate cotransporting polypeptide (NTCP). It hinders the secretion of viral capsid proteins HBsAg and HBeAg, with IC50 values of 0.65 µM and 13.42 µM, respectively, and inhibits HBV DNA replication with an IC50 of 0.70 µM.

AIC263282 is a potent capsid assembly modulator for the hepatitis B virus (HBV) with an EC50 of 3.8 nM. It exhibits an IC50 of 61 nM against hERG and effectively inhibits viral replication and hepatitis B surface antigen (HBsAG) in primary human hepatocytes.

HBV-IN-52 is a selective inhibitor of HBV and a derivative of Neplanocin A, displaying significant anti-hepatitis B virus replication activity with an EC50 of 0.96 μM. It also suppresses the secretion of hepatitis B surface antigen (HBsAg) with an EC50 of 0.82 μM. HBV-IN-52 is useful for studying chronic hepatitis B (CHB) infection.

HBV-IN-44 (Compound (S)-2a) is an HBV inhibitor with an IC50 value of 23 nM against HbsAg. It exhibits minimal toxicity in HT22 cells and in the neurite outgrowth of ex vivo mouse DRG neurons.

TLR7 agonist22 (Compound 11a) is a selective TLR7 agonist with an IC50 value of 25.86 μM. It inhibits the secretion of cell HBsAg and effectively activates TLR7, inducing the release of TLR7-regulated cytokines IL-12, TNF-α, and IFN-α in human PBMC cells. TLR7 agonist22 shows promise for developing novel immunomodulatory drugs in HBV research.

DF-006 is an innovative orally active agonist of ALPK1 (α-kinase 1). It stimulates the innate immune response in the liver by activating the NF-κB pathway. DF-006 effectively reduces serum levels of hepatitis B virus (HBV) DNA (EC50 = 2.7 pM), HBsAg, and HBeAg, demonstrating potent antiviral activity, making it suitable for immunotherapy research in chronic hepatitis B (CHB).

ALG-001075, a capsid assembly modulator (CAM), is an orally active inhibitor of HBV. It effectively suppresses HBV DNA production in primary human hepatocytes and significantly reduces extracellular levels of HBsAg/HBeAg and intracellular HBV RNA. In AAV-HBV mouse models, ALG-001075 notably decreases HBV DNA levels. It can be utilized in research related to chronic hepatitis B (CHB).

The nucleocapsid of the hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a. The four major subtypes of HBsAg, adw, adr, ayw and ayr, are generated, and they have been proposed to

Nirtetralin suppresses HBsAg and HBeAg expression.

Destruxin B2 is a cyclic hexadepsipeptide mycotoxin that has been found in M. anisopliae and has antiviral, insecticidal, and phytotoxic activities.1,2,3 It inhibits secretion of hepatitis B virus surface antigen (HBsAg) by Hep3B cells expressing hepatitis B virus (HBV) DNA (IC50 = 1.3 μM).1 Destruxin B2 is toxic to Sf9 insect cells in an electric cell-substrate impedance sensing (ECIS) test with a 50% inhibitory concentration (ECIS50) value of 92 μM.4 It is also phytotoxic to B. napus leaves.3 |1. Yeh, S.F., Pan, W., Ong, G.-T., et al. Study of structure-activity correlation in destruxins, a class of cyclodepsipeptides possessing suppressive effect on the generation of hepatitis B virus surface antigen in human hepatoma cells. Biochem. Biophys. Res. Commun. 229(1), 65-72 (1996).|2. Male, K.B., Tzeng, Y.-M., Montes, J., et al. Probing inhibitory effects of destruxins from Metarhizium anisopliae using insect cell based impedance spectroscopy: Inhibition vs chemical structure. Analyst 134(7), 1447-1452 (2009).|3. Buchwaldt, L., and Green, H. Phytotoxicity of destruxin B and its possible role in the pathogenesis of Alternaria brassicae. Plant Pathol. 41(1), 55-63 (1992).

Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is a natural product functioning as an apoptosis and autophagy inducer. Possessing oral bioavailability, this compound exhibits diverse pharmacological effects including antiviral and antitumor activities through modulation of the GSK3β/β-catenin and p53 signaling pathways.

HBV-IN-24 (compound (2 S, 6S)-1a) is a potent inhibitor of HBV. HBV-IN-24 is a strong inhibitor of HBV DNA (EC50: 0.6 nM), HBsAg (EC50: 0.6 nM) and HBeAg (EC50: 4.6 nM). antiviral effect and was able to improve neurotoxicity.

HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg).

HBV-IN-9 (example 20) is a potent inhibitor of HBsAg (HBV surface antigen) with an IC50 of 10 nM and also inhibits HBV DNA replication with an IC50 of 0.15 nM.

HBV-IN-11 is a potent inhibitor of HBsAg secretion (EC50: 0.46 μM).

(5S,8R)-HBV-IN-10, an isomer of compound 6 (WO2021204258A1), is a potent inhibitor of hepatitis B surface antigen (HBsAg) with an EC50 range of 0.1 μM to 1 μM.